Business Development Manager - Licensing

Biocytogen Boston Corp is a fast-growing biotech company at the forefront of innovation, equipped with broad cutting-edge technologies. Our expertise spans a wide range of therapeutic areas, including immuno-oncology , inflammatory and autoimmune diseases, neurology, cardiovascular and metabolic disorders, and more. At Biocytogen, you will have the unique opportunity to engage in both scientific and business endeavors, driving the licensing and commercialization of cutting-edge antibody assets across multiple therapeutic fields. The successful candidate will possess a strong understanding of business development and licensing and play a key role in driving strategic growth and exploring new business opportunities for the organization.

• →Establish external business opportunities for out-licensing, co-development, and other structured transactions.
• →Lead the development and presentation of business cases of prioritized external opportunities with recommendations to management team with robust analyses, key assumptions, and risks, as well as internal and external input where necessary.
• →Initiate, lead and present external opportunities with limited supervision.
• →Lead driving cross-functional due diligence and alliance management, coordinate with R&D, CMC, Clinical, Regulatory, Operations, and Finance and executive reporting, in some instances be the main BD contact person.
• →Follow BD operations and transactions including proposals and TS developments,negotiations, deal closure and alliance management.
• →Contribute to the definition and revision of business development & licensing strategy that is in line with overall corporate and portfolio strategies.
• →Represent Biocytogen at industry, investor and partnering conferences, develop and maintain relationships with a wide range of pharmaceutical/biotechnology industry participants.

• Ph.D. in pharmacology, immunology, cancer biology, or a related biomedical science field
• Strong background in antibody drug discovery, with a deep understanding of target validation and hit-to-lead optimization
• Proven ability to interpret complex biological data (affinity, specificity, and in vivo efficacy) and translate it into a compelling therapeutic and licensing narrative
• Familiarity with current antibody modalities, including monoclonal antibodies (mAbs), bispecific antibodies, and ADCs
• Strong strategic thinking skills to align internal scientific platform capabilities with pharmaceutical partner pipeline gaps